CAMBRIDGE, Mass., Dec. 11 /PRNewswire-FirstCall/ -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the
Company will be added to the NASDAQ-100 Index(R), effective with the market
open on Monday, December 18, 2006. Shares of Vertex will also be included
in the NASDAQ-100 Index Tracking Stock(R) (Nasdaq: QQQQ).
"Vertex is honored to be recognized as part of this year's NASDAQ-100
Index," said Joshua Boger, Ph.D., President and CEO of Vertex
Pharmaceuticals. "Our inaugural listing in the NASDAQ-100 reflects
significant achievements across our business in recent years. We look
forward to continued growth as the Company progresses in the development of
innovative therapies for the treatment of hepatitis C and other serious
diseases."
The NASDAQ-100 Index includes 100 of the largest domestic and
international non-financial securities listed on The NASDAQ Stock Market
based on market capitalization. First introduced in 1985, the index is
composed of many of the world's leading companies from major industry
groups including biotechnology, computer hardware and software,
telecommunications, and retail/wholesale trade. Index securities are ranked
by market value and reviewed on an annual basis. The NASDAQ-100 Index
Tracking Stock, launched in March 1999, is an exchange-traded fund (ETF)
designed to generally correspond to the price and yield performance of the
NASDAQ-100 Index. For more information on the NASDAQ-100 Index or the
NASDAQ-100 Index Tracking Stock, visit http://www.nasdaq-100.com.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is focused on viral diseases,
inflammation, autoimmune diseases, cancer, pain and bacterial infection.
Vertex co-discovered the HIV protease inhibitor, Lexiva, with
GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Safe Harbor Statement
This press release may contain forward-looking statements, including a
statement of the Company's expectation that it will continue to progress in
the development of innovative therapies for hepatitis C and other serious
diseases. While management makes its best efforts to be accurate in making
forward-looking statements, such statements are subject to risks and
uncertainties that could cause Vertex's actual results to vary materially.
These and other risks are listed under Risk Factors in Vertex's Form 10-K
filed with the Securities and Exchange Commission on March 16, 2006.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Contacts:
Lora Pike, Manager, Investor Relations, (617) 444-6755
Zachry Barber, Senior Media Relations Specialist, (617) 444-6470
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com
http://www.nasdaq-100.com
http://www.prnewswire.com/comp/938395.html/
CONTACT:
Lora Pike, Manager, Investor Relations,
+1-617-444-6755, or Zachry Barber, Senior Media Relations
Specialist, +1-617-444-6470, both of Vertex Pharmaceuticals
Incorporated
|
